Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

The requested reference [d79a8f4e0c9722383c3ad1f1de780d57b3bf961c] no longer exists in our database. It has been replaced by the current reference: [05e637eb8ec52afbd8d45ac5ce1ea81db7d01f23]

Authors Youngstown State University -More
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Links ClinicalTrials.gov
This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis \[NDHD\] patients receiving dialysis for ≤ 2 years. The project will aimed at providing proof-of-concept data that 80 U two times \[2x\] week Acthar for 6 months is a safe and effective therapy for NDHD. Effectiveness of lower dose 40 U 2X week will also be determined. Therefore the study will be a repeated measures design (Time x condition) comparison of improvement in renal function, nutritional status, quality of life and physical performance resulting from Acthar therapy.
Epistemonikos ID: 0870a56e0e353b600508b32da67e3ab576beb896
First added on: May 12, 2024